These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37665776)

  • 1. Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group.
    Karschnia P; Dietrich J; Bruno F; Dono A; Juenger ST; Teske N; Young JS; Sciortino T; Häni L; van den Bent M; Weller M; Vogelbaum MA; Morshed RA; Haddad AF; Molinaro AM; Tandon N; Beck J; Schnell O; Bello L; Hervey-Jumper S; Thon N; Grau SJ; Esquenazi Y; Rudà R; Chang SM; Berger MS; Cahill DP; Tonn JC
    Neuro Oncol; 2024 Jan; 26(1):166-177. PubMed ID: 37665776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
    Karschnia P; Dono A; Young JS; Juenger ST; Teske N; Häni L; Sciortino T; Mau CY; Bruno F; Nunez L; Morshed RA; Haddad AF; Weller M; van den Bent M; Beck J; Hervey-Jumper S; Molinaro AM; Tandon N; Rudà R; Vogelbaum MA; Bello L; Schnell O; Grau SJ; Chang SM; Berger MS; Esquenazi Y; Tonn JC
    Neuro Oncol; 2023 Sep; 25(9):1672-1685. PubMed ID: 37253096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group.
    Karschnia P; Young JS; Dono A; Häni L; Sciortino T; Bruno F; Juenger ST; Teske N; Morshed RA; Haddad AF; Zhang Y; Stoecklein S; Weller M; Vogelbaum MA; Beck J; Tandon N; Hervey-Jumper S; Molinaro AM; Rudà R; Bello L; Schnell O; Esquenazi Y; Ruge MI; Grau SJ; Berger MS; Chang SM; van den Bent M; Tonn JC
    Neuro Oncol; 2023 May; 25(5):940-954. PubMed ID: 35961053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
    Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
    JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification.
    Tropeano MP; Raspagliesi L; Bono BC; Baram A; Rossini Z; Franzini A; Navarria P; Clerici E; Bellu L; Simonelli M; Scorsetti M; Riva M; Politi LS; Pessina F
    Acta Neurochir (Wien); 2024 Apr; 166(1):196. PubMed ID: 38676720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extending the resection beyond the contrast-enhancement for glioblastoma: feasibility, efficacy, and outcomes.
    Mampre D; Ehresman J; Pinilla-Monsalve G; Osorio MAG; Olivi A; Quinones-Hinojosa A; Chaichana KL
    Br J Neurosurg; 2018 Oct; 32(5):528-535. PubMed ID: 30073866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
    Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
    J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of radiological findings on early postoperative MRI for 187 consecutive glioblastoma patients receiving standard therapy.
    Rykkje AM; Carlsen JF; Larsen VA; Skjøth-Rasmussen J; Christensen IJ; Nielsen MB; Poulsen HS; Urup TH; Hansen AE
    Sci Rep; 2024 May; 14(1):10985. PubMed ID: 38744979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma.
    Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A
    J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma.
    Incekara F; Smits M; van der Voort SR; Dubbink HJ; Atmodimedjo PN; Kros JM; Vincent AJPE; van den Bent M
    Front Oncol; 2020; 10():1087. PubMed ID: 32766140
    [No Abstract]   [Full Text] [Related]  

  • 13. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.
    Lohmann P; Stavrinou P; Lipke K; Bauer EK; Ceccon G; Werner JM; Neumaier B; Fink GR; Shah NJ; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):591-602. PubMed ID: 30327856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Peritumoral Brain Parenchyma Using Contrast-Enhanced 3D Fast Imaging Employing Steady-State Acquisition at 3T for Differentiating Metastatic Brain Tumors and Glioblastomas.
    Yamamoto J; Kakeda S; Shimajiri S; Nakano Y; Saito T; Ide S; Moriya J; Korogi Y; Nishizawa S
    World Neurosurg; 2018 Dec; 120():e719-e729. PubMed ID: 30165229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance.
    Neira JA; Ung TH; Sims JS; Malone HR; Chow DS; Samanamud JL; Zanazzi GJ; Guo X; Bowden SG; Zhao B; Sheth SA; McKhann GM; Sisti MB; Canoll P; D'Amico RS; Bruce JN
    J Neurosurg; 2017 Jul; 127(1):111-122. PubMed ID: 27715437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study.
    Bjorland LS; Mahesparan R; Fluge Ø; Gilje B; Dæhli Kurz K; Farbu E
    Neurooncol Adv; 2023; 5(1):vdad126. PubMed ID: 37868696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic histopathological analysis of different 5-aminolevulinic acid-induced fluorescence levels in newly diagnosed glioblastomas.
    Kiesel B; Mischkulnig M; Woehrer A; Martinez-Moreno M; Millesi M; Mallouhi A; Czech T; Preusser M; Hainfellner JA; Wolfsberger S; Knosp E; Widhalm G
    J Neurosurg; 2018 Aug; 129(2):341-353. PubMed ID: 29076783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of MRI contrast enhancement in newly diagnosed glioblastoma, IDH-wildtype according to WHO 2021 classification.
    Roux A; Elia A; Hudelist B; Benzakoun J; Dezamis E; Parraga E; Moiraghi A; Simboli GA; Chretien F; Oppenheim C; Zanello M; Pallud J
    J Neurooncol; 2024 Sep; 169(2):445-455. PubMed ID: 38913230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial.
    Roder C; Stummer W; Coburger J; Scherer M; Haas P; von der Brelie C; Kamp MA; Löhr M; Hamisch CA; Skardelly M; Scholz T; Schipmann S; Rathert J; Brand CM; Pala A; Ernemann U; Stockhammer F; Gerlach R; Kremer P; Goldbrunner R; Ernestus RI; Sabel M; Rohde V; Tabatabai G; Martus P; Bisdas S; Ganslandt O; Unterberg A; Wirtz CR; Tatagiba M
    J Clin Oncol; 2023 Dec; 41(36):5512-5523. PubMed ID: 37335962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which Parameter Is More Important for the Prognosis of New-Onset Adult Glioblastoma: Residual Tumor Volume or Extent of Resection?
    Xing Y; Wang X
    World Neurosurg; 2018 Aug; 116():e444-e451. PubMed ID: 29753893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.